THE agenda for the March 2026 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) is now available online.
Among items for consideration is an application for the PBS listing of adrenaline nasal spray Neffy (Seqirus) for the emergency treatment of severe allergic reactions with anaphylaxis.
Also on the list is a request to change to the National Immunisation Program (NIP) listing of Arexvy (GSK) to extend eligibility to individuals aged 60 to 74 years who are at high risk of lower respiratory tract disease caused by RSV, while Celltrion has requested PBS listing of two new forms of its omalizumab biosimilar Omlyclo for severe asthma and urticaria.
PBAC welcomes comment from any interested party before the consultation closing date of 21 Jan 2026 - the agenda is HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 25
